Company: IMCR
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001140361-25-007867
Chunk: 0

Company: Immunocore Holdings plc
Filing Date: 2025-03-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure  

On March 10, 2025, Immunocore Holdings plc (the “ Company”) issued a press release announcing the presentation of initial data from the ongoing multiple
ascending dose (MAD) portion of the Company’s Phase 1/2 STRIVE trial of IMC-M113V in people living with human immunodeficiency virus. As disclosed in the press release, the Company presented such data in an oral session at the Conference on
Retroviruses and Opportunistic Infections (CROI) 2025, held earlier today in San Francisco, California. The Company presented data which shows that, as of the completion of the third cohort of the trial, IMC-M113V was observed to be well tolerated
and shows signals of dose-dependent reduction in active reservoir, and viral control after antiretroviral treatment was interrupted. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by
reference herein.

On March 10, 2025, the Company also made an investor presentation available on the
"Investors/Media" section of the Company's website at www. immunocore. com summarizing the initial data from the MAD portion of the STRIVE trial presented at CROI 2025. The presentation will be used at one-on-one meetings with analysts and investors from time to time. The Company's website and any information contained on
the Company's website are not incorporated by reference into this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.